Targeted radiation shows promise for Tough-to-Treat prostate cancer
NCT ID NCT05219500
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a drug called FPI-2265, which delivers targeted radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The study will measure how well the drug lowers PSA levels and monitor side effects in 115 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FPI-2265 (a targeted radiation therapy that seeks out prostate cancer cells)
What this could lead to
If successful, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a mid-stage trial with only 115 participants, so results may not apply to everyone. The treatment involves radioactive material, which can cause side effects like dry mouth or kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas, 77042, United States
-
XCancer Omaha/Urology Cancer Center
Omaha, Nebraska, 68130, United States